PAG, an Asia-focussed private equity firm, along with its consortium partners CX Partners and Samara Capital, is all set to acquire a controlling stake in Anjan Drug Pvt. Ltd, a Chennai-based manufacturer of active pharmaceutical ingredients (API).However, the terms of the deal were not disclosed.The acquisition is part of the PAG-led consortium’s strategy to create a platform for the development and production of bulk drug ingredients, PAG said in a statement.“We see the Indian API market as a very attractive opportunity and well-positioned for the future,” said Nikhil Srivastava, managing director and head, India private equity, PAG.
A letter from the Editor
Dear subscriber,Thank you!Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.Suresh Nambath